Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis

Coelho, Pedro Luiz Spinelli; Calestini, Gustavo Lacerda da Silva; Alvo, Fernando Salgueiro; Freitas, Jefferson Michel de Moura; Castro, Paula Marcela Vilela; Konstantyner, Túlio

doi:10.1016/j.rppede.2015.08.017

Cited by 3 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three reviews [ 37 , 42 , 43 ], reported on the impact of vaccination on maternal and perinatal outcomes. Two reported on the provision of the human papillomavirus vaccine (HPV) [ 37 , 43 ], and one reported on the herpes simplex virus (HSV) vaccine [ 42 ].…”

Section: Resultsmentioning

confidence: 99%

Exploring preconception health in adolescents and young adults: Identifying risk factors and interventions to prevent adverse maternal, perinatal, and child health outcomes–A scoping review

Padhani,

Rahim,

Tessema

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background Preconception health provides an opportunity to examine a woman’s health status and address modifiable risk factors that can impact both a woman’s and her child’s health once pregnant. In this review, we aimed to investigate the preconception risk factors and interventions of early pregnancy and its impact on adverse maternal, perinatal and child health outcomes. Methods We conducted a scoping review following the PRISMA-ScR guidelines to include relevant literature identified from electronic databases. We included reviews that studied preconception risk factors and interventions among adolescents and young adults, and their impact on maternal, perinatal, and child health outcomes. All identified studies were screened for eligibility, followed by data extraction, and descriptive and thematic analysis. Findings We identified a total of 10 reviews. The findings suggest an increase in odds of maternal anaemia and maternal deaths among young mothers (up to 17 years) and low birth weight (LBW), preterm birth, stillbirths, and neonatal and perinatal mortality among babies born to mothers up to 17 years compared to those aged 19–25 years in high-income countries. It also suggested an increase in the odds of congenital anomalies among children born to mothers aged 20–24 years. Furthermore, cancer treatment during childhood or young adulthood was associated with an increased risk of preterm birth, LBW, and stillbirths. Interventions such as youth-friendly family planning services showed a significant decrease in abortion rates. Micronutrient supplementation contributed to reducing anaemia among adolescent mothers; however, human papillomavirus (HPV) and herpes simplex virus (HSV) vaccination had little to no impact on stillbirths, ectopic pregnancies, and congenital anomalies. However, one review reported an increased risk of miscarriages among young adults associated with these vaccinations. Conclusion The scoping review identified a scarcity of evidence on preconception risk factors and interventions among adolescents and young adults. This underscores the crucial need for additional research on the subject.

show abstract

Section: Resultsmentioning

confidence: 99%

Exploring preconception health in adolescents and young adults: Identifying risk factors and interventions to prevent adverse maternal, perinatal, and child health outcomes–A scoping review

Padhani,

Rahim,

Tessema

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…In a systematic review study and meta-analysis of clinical trials [6] major adverse effects associated with the application of the HPV quadrivalent vaccine were identified, and the results showed that the main effects were local, such as pain, erythema and edema, and seen as a systemic effect fever. 2014 campaign data in Brazil showed that the total of 4,159,335 doses, 854 adverse events were reported, classified as non-serious adverse event, with 810 cases and 253 syncopation; and serious adverse events, anaphylaxis (9), convulsion (8), optic neuritis (2), Bell's palsy (1) (10).…”

Section: Discussionmentioning

confidence: 99%

“…Among these diseases, infection with Human Papillomavirus -HPV, has shown high prevalence among Sexually Transmitted Infections -STI worldwide. Factor associated with the development of cervical cancer and other cancers, HPV has been responsible for the death of thousands of women [4][5][6]. The development of HPV infection may be transient and not clinically detectable, however, can cause warts and a variety of anogenital premalignant and malignant lesions to cancer of the cervix in women and penis cancer in men [6,7].…”

Section: Introductionmentioning

confidence: 99%

“…Factor associated with the development of cervical cancer and other cancers, HPV has been responsible for the death of thousands of women [4][5][6]. The development of HPV infection may be transient and not clinically detectable, however, can cause warts and a variety of anogenital premalignant and malignant lesions to cancer of the cervix in women and penis cancer in men [6,7].In 2006, aimed the preventing, the Food and Drug Administration (FDA), american agency that regulates food and drugs, approved the quadrivalent prophylactic vaccine for HPV 6, 11, 16 and 18, increasing the actions against cervical cancer [8][9]. In the same year, the National Health Surveillance Agency -ANVISA, regulated the sale of quadrivalent vaccine in Brazil [4,9].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Analysis Of Vaccination Campaign Against Hpv And The Perspective Of Vaccinated Population

Nunes¹,

Medeiros²,

Sáfadi³

et al. 2017

int arch med

View full text Add to dashboard Cite

Introduction: The Ministry of Health has provided for the girls population aged nine to 13 years, the quadrivalent vaccine against Human Papillomavirus as a preventive measure for cancer of the cervix, with the initial proposal to achieve 80% of this population.Objective: To analyze the vaccine coverage and the perspective of the target population about the vaccine against the Human Papillomavirus. Methods:This was a quantitative and qualitative field research in descriptive character, conducted through the Information System of the National Program for Immunization and with a sample of 86 adolescents in the city of São José do Egito/PE/BR. Results:The vaccination coverage showed a reduction in sequence of the vaccination schedules of 19.53% in the first phase of the campaign and of 24.07% in the second phase. It was also noted that lack accurate information for more than 50% of respondents, 15.11% had local and/or systemic reactions and 89,53% of them expect positive results with the vaccine against the Human Papillomavirus. Analysis of Vaccination IntroductionCurrently, through the National Immunization Program -NIP, Brazil has a basic schedule free vaccination that caters to children, adolescents, pregnant women, adult, elderly, indigenous and even groups with special conditions, offered in Immunobiology Special centers -CRIES, offering more than 20 types of biopharmaceuticals, being a great ally of public health actions and the basis for the prevention of immunopreventable diseases [1][2][3]. Among these diseases, infection with Human Papillomavirus -HPV, has shown high prevalence among Sexually Transmitted Infections -STI worldwide. Factor associated with the development of cervical cancer and other cancers, HPV has been responsible for the death of thousands of women [4][5][6]. The development of HPV infection may be transient and not clinically detectable, however, can cause warts and a variety of anogenital premalignant and malignant lesions to cancer of the cervix in women and penis cancer in men [6,7].In 2006, aimed the preventing, the Food and Drug Administration (FDA), american agency that regulates food and drugs, approved the quadrivalent prophylactic vaccine for HPV 6, 11, 16 and 18, increasing the actions against cervical cancer [8][9]. In the same year, the National Health Surveillance Agency -ANVISA, regulated the sale of quadrivalent vaccine in Brazil [4,9].It is estimated that in Brazil only in 2014, according to the National Cancer Institute -INCA, 15,590 new cases of cervical cancer were diagnosed [8]. Given this focus, the Ministry of Health -MS, introduced the vaccine in the National Immunization Schedule, providing a significant increase in the perspective of prevention of cervical cancer, in conjunction with the screening actions existing in care programs for woman health. Initially, the vaccine was available to a population made up of girls from 11 to 13 years, with a proposal to achieve up to 80% of the target audience [10,11]. When performing campaigns, the MS defines strate...

show abstract

“…Thus, a meta-analysis is a suitable resolution to overcome such problems. Previous meta-analyses did not support the specified AEFIs with the use of HPVv 53–55. Although another research group recently suggested a high risk of topical reactions at the injection site,19 20 we must assess whether an adjuvant evokes such topical reactions.…”

Section: Ethics and Disseminationmentioning

confidence: 93%

Adverse events associated with human papillomavirus vaccines: a protocol for systematic review with network meta-analysis incorporating all randomised controlled trials comparing with placebo, adjuvants and other vaccines

et al. 2019

View full text Add to dashboard Cite

IntroductionAdverse events following the injection (AEFIs) of human papillomavirus vaccine (HPVv) among female adolescents are still a major public health concern.MethodsAccording to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension statement for systematic reviews incorporating network meta-analyses, all prospective randomised trials will be included. The primary outcome for adverse events is topical pain during the observation period.We will mainly search 17 electronic databases from January 2000 through September 2019 with suitable Medical Subject Headings and text words for PubMed. Two reviewers will independently check the reports at the title/abstract level and identify potentially applicable studies. Then we will obtain their full texts and decide whether to include them based on the same eligible criteria.We will compare HPVv with placebo, HPVv with adjuvant and HPVv with other vaccines. Interstudy heterogeneity, publication biases or small study effects will be evaluated using conventional meta-analysis methods. The consistency of the network will be checked using tests for local and global inconsistency and the side-splitting method. To address the heterogeneity of treatment effects among the studies, we will use the multivariable random effect model.Ethics and disseminationThis pairwise or network meta-analysis does not require ethics approval. The data used here are not individual nor private. We will be able to determine which component of the vaccine induces adverse events, especially topical pain. This systematic review with network meta-analysis will provide valid answers regarding AEFIs for HPVv.PROSPERO registration numberCRD42018109265

show abstract

Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis

Cited by 3 publications

References 40 publications

Exploring preconception health in adolescents and young adults: Identifying risk factors and interventions to prevent adverse maternal, perinatal, and child health outcomes–A scoping review

Exploring preconception health in adolescents and young adults: Identifying risk factors and interventions to prevent adverse maternal, perinatal, and child health outcomes–A scoping review

Analysis Of Vaccination Campaign Against Hpv And The Perspective Of Vaccinated Population

Adverse events associated with human papillomavirus vaccines: a protocol for systematic review with network meta-analysis incorporating all randomised controlled trials comparing with placebo, adjuvants and other vaccines

Contact Info

Product

Resources

About